Details for Patent: 6,673,337
✉ Email this page to a colleague
Title: | Compositions containing alpha-2-adrenergic agonist components |
Abstract: | Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose. |
Inventor(s): | Olejnik; Orest (Coto de Coza, CA), Kerslake; Edward D. S. (Charlestown, MA) |
Assignee: | Allergan, Inc. (Irvine, CA) |
Filing Date: | Nov 19, 2002 |
Application Number: | 10/299,386 |
Claims: | 1. A therapeutically effective ophthalmic composition comprising: an alpha-2-adrenergic agonist component in an amount effective to provide a therapeutic benefit to a patient to whom the composition is administered; and a solubility enhancing component other than a cyclodextrin in an amount effective to increase the solubility of the alpha-2-adrenergic agonist component in the composition relataive to the solubility of an identical alpha-2-adrenergic agonist component in a similar composition without the solubility enhancing component. 2. The composition of claim 1 wherein the alpha-2-adrenergic component is selected from the group consisting of imino-imidazolines, imidazolines, imidazoles, azepines, thiazines, oxazolines, guanidines, catecholamines, derivatives thereof, and mixtures thereof. 3. The composition of claim 1 wherein the therapeutically active component includes a quinoxaline component. 4. The composition of claim 3 wherein the quinoxaline component is selected from the group consisting of quinoxaline, derivatives thereof, and mixtures thereof. 5. The composition of claim 1 wherein said solubility enhancing component comprises an anionic polymer. 6. The composition of claim 1 wherein the solubility enhancing component is effective to increase the solubility in a biological environment of the alpha-2-adrenergic agonist component relative to the solubility in a biological environment of an identical alpha-2-adrenergic agonist component in a similar composition without the solubility enhancing component. 7. The composition of claim 6 wherein the solubility enhancing component comprises an anionic polymer. 8. The composition of claim 3 wherein said solubility enhancing component comprisers an anionic polymer. 9. The composition of claim 1 which further comprises an effective amount of a preservative. 10. The composition of claim 6 which further comprises an effective amount of a preservative. |